{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T18:41:03Z","timestamp":1792176063994,"version":"4.4.0"},"reference-count":95,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,18]],"date-time":"2025-05-18T00:00:00Z","timestamp":1747526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,18]],"date-time":"2025-05-18T00:00:00Z","timestamp":1747526400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Dissecting cellulitis of the scalp (DCS) is a type of neutrophilic scarring alopecia identified by the development of folliculitis with clusters of perifollicular pustules and then progresses to abscesses and intercommunicating sinus formation. In the absence of evidence-based guidelines, the treatment of DCS remains a therapeutic challenge. Our study aimed to assess the safety and efficacy of biologics, including tumor necrosis factor-\u03b1 (TNF-\u03b1) blockers, anti-interleukins (ILs), and small molecule inhibitors, including Janus kinase (JAK) inhibitors and phosphodiesterase inhibitors in treating DCS.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>PubMed\/Medline, Scopus, and Ovid Embase databases were systematically searched until February 4th, 2024. Study selection was restricted to case reports, case series, cohort studies, and clinical trials published in English-language. NIH and Murad et al.\u2019s quality assessment tools were utilized for critical appraisal.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>A total of 34 articles involving 81 patients met the inclusion criteria. The immunomodulators studied for the treatment of DCS include adalimumab, infliximab, certolizumab pegol, ustekinumab, secukinumab, guselkumab, risankizumab, tildrakizumab, apremilast, upadacitinib, and baricitinib. Our findings implied that TNF-\u03b1 blockers and IL inhibitors were associated with clinical improvement in most individuals with moderate-to-severe DCS, especially in those who had failed earlier treatments. Moreover, certolizumab pegol could be a safe option for DCS in pregnancy. In addition, the prescription of small molecule inhibitors, including JAK inhibitors and apremilast in DCS patients, demonstrated a significant amelioration in DCS symptoms with a desirable safety profile. Nevertheless, the available data was limited, warranting further investigation. Besides, all aforementioned immunomodulators are still debated for their effectiveness on hair regrowth and reversing the scarring process.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>The application of immunomodulators in treating DCS was associated with satisfactory outcomes, although there is still a need to assess the long-term safety and effectiveness of these therapeutic agents in preventing disease progression and new flare-ups.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13023-025-03720-5","type":"journal-article","created":{"date-parts":[[2025,5,18]],"date-time":"2025-05-18T09:00:43Z","timestamp":1747558843000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["A systematic review of tumor necrosis factor-\u03b1 blockers, anti-interleukins, and small molecule inhibitors for dissecting cellulitis of the scalp treatment"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7259-4926","authenticated-orcid":false,"given":"Nazila","family":"Heidari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4707-6407","authenticated-orcid":false,"given":"Rad","family":"Ghannadzadeh Kermani Pour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3698-2363","authenticated-orcid":false,"given":"Melina","family":"Farshbafnadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4327-8814","authenticated-orcid":false,"given":"Amirhossein","family":"Heidari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7309-4066","authenticated-orcid":false,"given":"Yekta","family":"Ghane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,18]]},"reference":[{"issue":"8","key":"3720_CR1","doi-asserted-by":"publisher","first-page":"e3015","DOI":"10.1097\/GOX.0000000000003015","volume":"8","author":"TA Cuellar","year":"2020","unstructured":"Cuellar TA, Roh DS, Sampson CE. Dissecting cellulitis of the scalp: a review and case studies of surgical reconstruction. Plast Reconstr Surg Glob Open. 2020;8(8):e3015.","journal-title":"Plast Reconstr Surg Glob Open"},{"key":"3720_CR2","doi-asserted-by":"publisher","first-page":"2959140","DOI":"10.1155\/2023\/2959140","volume":"2023","author":"AH Ehsani","year":"2023","unstructured":"Ehsani AH, Yolme H, Akhavan Sabagh M, Azhari V, Kianfar N, Aryanian Z. Demographic and histopathological evaluation in 71 patients diagnosed with dissecting cellulitis of the scalp. Dermatol Ther. 2023;2023:2959140.","journal-title":"Dermatol Ther"},{"issue":"11","key":"3720_CR3","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1001\/jamadermatol.2016.2743","volume":"152","author":"E Asemota","year":"2016","unstructured":"Asemota E, Chang YC, Goldberg LJ. Innovative management of recalcitrant dissecting cellulitis with compression therapy. JAMA Dermatol. 2016;152(11):1280\u20131.","journal-title":"JAMA Dermatol"},{"issue":"4","key":"3720_CR4","doi-asserted-by":"publisher","first-page":"173","DOI":"10.4103\/0974-7753.171584","volume":"7","author":"VL Gaopande","year":"2015","unstructured":"Gaopande VL, Kulkarni MM, Joshi AR, Dhande AN. Perifolliculitis capitis abscedens et suffodiens in a 7\u00a0years male: a case report with review of literature. Int J Trichol. 2015;7(4):173\u20135.","journal-title":"Int J Trichol"},{"issue":"9","key":"3720_CR5","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1111\/1346-8138.14998","volume":"46","author":"T Takahashi","year":"2019","unstructured":"Takahashi T, Yamasaki K, Terui H, Omori R, Tsuchiyama K, Fujimura T, Aiba S. Perifolliculitis capitis abscedens et suffodiens treatment with tumor necrosis factor inhibitors: a case report and review of published cases. J Dermatol. 2019;46(9):802\u20137.","journal-title":"J Dermatol"},{"issue":"5","key":"3720_CR6","doi-asserted-by":"publisher","first-page":"22692","DOI":"10.5070\/D3205022692","volume":"20","author":"N Scheinfeld","year":"2014","unstructured":"Scheinfeld N. Dissecting cellulitis (Perifolliculitis Capitis Abscedens et Suffodiens): a comprehensive review focusing on new treatments and findings of the last decade with commentary comparing the therapies and causes of dissecting cellulitis to hidradenitis suppurativa. Dermatol Online J. 2014;20(5):22692.","journal-title":"Dermatol Online J"},{"issue":"3","key":"3720_CR7","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.clindermatol.2021.01.002","volume":"39","author":"A Federico","year":"2021","unstructured":"Federico A, Rossi A, Caro G, Magri F, Muscianese M, Di Fraia M, Carlesimo M. Are dissecting cellulitis and hidradenitis suppurativa different diseases? Clin Dermatol. 2021;39(3):496\u20139.","journal-title":"Clin Dermatol"},{"key":"3720_CR8","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.clindermatol.2023.08.021","volume":"41","author":"B Jastrz\u0105b","year":"2023","unstructured":"Jastrz\u0105b B, Szepietowski JC, Matusiak \u0141. Hidradenitis suppurativa and follicular occlusion syndrome: where is the pathogenetic link? Clin Dermatol. 2023;41:576.","journal-title":"Clin Dermatol"},{"key":"3720_CR9","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1007\/s13555-023-01018-7","volume":"13.11","author":"R Masson","year":"2023","unstructured":"Masson R, Jeong CY, Ma E, Crew AB, Fragoso NM, Shi VY, Hsiao JL. Treatments for dissecting cellulitis of the scalp: a systematic review and treatment algorithm. Dermatol Ther (Heidelb). 2023;13.11:2487.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"3720_CR10","doi-asserted-by":"publisher","first-page":"105","DOI":"10.2147\/CCID.S111019","volume":"10","author":"M Napolitano","year":"2017","unstructured":"Napolitano M, Megna M, Timoshchuk EA, Patruno C, Balato N, Fabbrocini G, Monfrecola G. Hidradenitis suppurativa: from pathogenesis to diagnosis and treatment. Clin Cosmet Investig Dermatol. 2017;10:105\u201315.","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"3720_CR11","unstructured":"Justiz Vaillant AA, Qurie A: Interleukin. In: StatPearls. Treasure Island (FL): StatPearls Publishing Copyright \u00a9 2023, StatPearls Publishing LLC.; 2023"},{"issue":"8","key":"3720_CR12","doi-asserted-by":"publisher","first-page":"7185","DOI":"10.3390\/ijms24087185","volume":"24","author":"H Liu","year":"2023","unstructured":"Liu H, Santos LL, Smith SH. Modulation of disease-associated pathways in hidradenitis suppurativa by the janus kinase 1 inhibitor povorcitinib: transcriptomic and proteomic analyses of two phase 2 studies. Int J Mol Sci. 2023;24(8):7185.","journal-title":"Int J Mol Sci"},{"issue":"9","key":"3720_CR13","doi-asserted-by":"publisher","first-page":"e0203672","DOI":"10.1371\/journal.pone.0203672","volume":"13","author":"LK Hoffman","year":"2018","unstructured":"Hoffman LK, Tomalin LE, Schultz G, Howell MD, Anandasabapathy N, Alavi A, Suarez-Farinas M, Lowes MA. Integrating the skin and blood transcriptomes and serum proteome in hidradenitis suppurativa reveals complement dysregulation and a plasma cell signature. PLoS ONE. 2018;13(9):e0203672.","journal-title":"PLoS ONE"},{"key":"3720_CR14","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.3389\/fimmu.2022.960488","volume":"13","author":"D Chopra","year":"2022","unstructured":"Chopra D, Arens RA, Amornpairoj W, Lowes MA, Tomic-Canic M, Strbo N, Lev-Tov H, Pastar I. Innate immunity and microbial dysbiosis in hidradenitis suppurativa\u2014vicious cycle of chronic inflammation. Front Immunol. 2022;13:1664\u20133224.","journal-title":"Front Immunol"},{"key":"3720_CR15","first-page":"ic17","volume":"14","author":"MA Jerome","year":"2014","unstructured":"Jerome MA, Laub DR. Dissecting cellulitis of the scalp: case discussion, unique considerations, and treatment options. Eplasty. 2014;14:ic17.","journal-title":"Eplasty"},{"key":"3720_CR16","first-page":"1558","volume":"134","author":"KR van Straalen","year":"2024","unstructured":"van Straalen KR, Ma F, Tsou PS, Plazyo O, Gharaee-Kermani M, Calbet M, Xing X, Sarkar MK, Uppala R, Harms PW, et al. Single-cell sequencing reveals hippo signaling as a driver of fibrosis in hidradenitis suppurativa. J Clin Investig. 2024;134:1558\u20138238.","journal-title":"J Clin Investig"},{"key":"3720_CR17","doi-asserted-by":"publisher","first-page":"594735","DOI":"10.3389\/fimmu.2020.594735","volume":"11","author":"T Liu","year":"2020","unstructured":"Liu T, Li S, Ying S, Tang S, Ding Y, Li Y, Qiao J, Fang H. The IL-23\/IL-17 pathway in inflammatory skin diseases: from bench to bedside. Front Immunol. 2020;11:594735.","journal-title":"Front Immunol"},{"issue":"11","key":"3720_CR18","doi-asserted-by":"publisher","first-page":"2389","DOI":"10.1016\/j.jid.2017.05.033","volume":"137","author":"B Moran","year":"2017","unstructured":"Moran B, Sweeney CM, Hughes R, Malara A, Kirthi S, Tobin AM, Kirby B, Fletcher JM. Hidradenitis suppurativa is characterized by dysregulation of the Th17: treg cell axis, which is corrected by Anti-TNF therapy. J Invest Dermatol. 2017;137(11):2389\u201395.","journal-title":"J Invest Dermatol"},{"key":"3720_CR19","doi-asserted-by":"publisher","first-page":"204062231985164","DOI":"10.1177\/2040622319851640","volume":"10","author":"KT Savage","year":"2019","unstructured":"Savage KT, Flood KS, Porter ML, Kimball AB. TNF-\u03b1 inhibitors in the treatment of hidradenitis suppurativa. Ther Adv Chronic Dis. 2019;10:2040622319851640.","journal-title":"Ther Adv Chronic Dis"},{"issue":"3","key":"3720_CR20","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1002\/jvc2.51","volume":"1","author":"Y Koike","year":"2022","unstructured":"Koike Y, Hattori N, Murota H. Serum cytokine\/chemokine levels in a patient with perifolliculitis capitis abscedens et suffodiens (dissecting cellulitis) successfully treated with the tumour necrosis factor \u03b1 inhibitor adalimumab. JEADV Clin Pract. 2022;1(3):271\u20134.","journal-title":"JEADV Clin Pract"},{"issue":"1","key":"3720_CR21","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.alit.2021.10.004","volume":"71","author":"C Nakashima","year":"2022","unstructured":"Nakashima C, Yanagihara S, Otsuka A. Innovation in the treatment of atopic dermatitis: emerging topical and oral janus kinase inhibitors. Allergol Int. 2022;71(1):40\u20136.","journal-title":"Allergol Int"},{"key":"3720_CR22","doi-asserted-by":"publisher","first-page":"519","DOI":"10.2147\/JIR.S219586","volume":"13","author":"R Harrington","year":"2020","unstructured":"Harrington R, Al Nokhatha SA, Conway R. JAK inhibitors in rheumatoid arthritis: an evidence-based review on the emerging clinical data. J Inflamm Res. 2020;13:519\u201331.","journal-title":"J Inflamm Res"},{"issue":"4","key":"3720_CR23","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1080\/25785826.2020.1770948","volume":"43","author":"A Morinobu","year":"2020","unstructured":"Morinobu A. JAK inhibitors for the treatment of rheumatoid arthritis. Immunol Med. 2020;43(4):148\u201355.","journal-title":"Immunol Med"},{"issue":"2","key":"3720_CR24","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.jaad.2009.06.050","volume":"62","author":"A Grant","year":"2010","unstructured":"Grant A, Gonzalez T, Montgomery MO, Cardenas V, Kerdel FA. Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial. J Am Acad Dermatol. 2010;62(2):205\u201317.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"3720_CR25","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1056\/NEJMoa1504370","volume":"375","author":"AB Kimball","year":"2016","unstructured":"Kimball AB, Okun MM, Williams DA, Gottlieb AB, Papp KA, Zouboulis CC, Armstrong AW, Kerdel F, Gold MH, Forman SB, et al. Two phase 3 trials of adalimumab for hidradenitis suppurativa. N Engl J Med. 2016;375(5):422\u201334.","journal-title":"N Engl J Med"},{"issue":"10378","key":"3720_CR26","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S0140-6736(23)00022-3","volume":"401","author":"AB Kimball","year":"2023","unstructured":"Kimball AB, Jemec GBE, Alavi A, Reguiai Z, Gottlieb AB, Bechara FG, Paul C, Giamarellos Bourboulis EJ, Villani AP, Schwinn A, et al. Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials. Lancet. 2023;401(10378):747\u201361.","journal-title":"Lancet"},{"issue":"5","key":"3720_CR27","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1007\/s13555-023-00913-3","volume":"13","author":"AB Kimball","year":"2023","unstructured":"Kimball AB, Prens EP, Passeron T, Maverakis E, Turchin I, Beeck S, Drogaris L, Geng Z, Zhan T, Messina I, et al. Efficacy and safety of risankizumab for the treatment of hidradenitis suppurativa: a phase 2, randomized. Placebo-Controll Trial Dermatol Ther (Heidelb). 2023;13(5):1099\u2013111.","journal-title":"Placebo-Controll Trial Dermatol Ther (Heidelb)"},{"issue":"5","key":"3720_CR28","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1111\/bjd.20969","volume":"186","author":"A Alavi","year":"2022","unstructured":"Alavi A, Hamzavi I, Brown K, Santos LL, Zhu Z, Liu H, Howell MD, Kirby JS. Janus kinase 1 inhibitor INCB054707 for patients with moderate-to-severe hidradenitis suppurativa: results from two phase II studies. Br J Dermatol. 2022;186(5):803\u201313.","journal-title":"Br J Dermatol"},{"issue":"3","key":"3720_CR29","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.jaad.2023.10.034","volume":"90","author":"JS Kirby","year":"2024","unstructured":"Kirby JS, Okun MM, Alavi A, Bechara FG, Zouboulis CC, Brown K, Santos LL, Wang A, Bibeau KB, Kimball AB, et al. Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib (INCB054707) in patients with hidradenitis suppurativa in a phase 2, randomized, double-blind, dose-ranging, placebo-controlled study. J Am Acad Dermatol. 2024;90(3):521\u20139.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"3720_CR30","doi-asserted-by":"publisher","first-page":"e14261","DOI":"10.1111\/dth.14261","volume":"33","author":"D Nassim","year":"2020","unstructured":"Nassim D, Alajmi A, Jfri A, Pehr K. Apremilast in dermatology: a review of literature. Dermatol Ther. 2020;33(6):e14261.","journal-title":"Dermatol Ther"},{"issue":"1","key":"3720_CR31","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.jaad.2018.06.046","volume":"80","author":"A Vossen","year":"2019","unstructured":"Vossen A, van Doorn MBA, van der Zee HH, Prens EP. Apremilast for moderate hidradenitis suppurativa: results of a randomized controlled trial. J Am Acad Dermatol. 2019;80(1):80\u20138.","journal-title":"J Am Acad Dermatol"},{"key":"3720_CR32","doi-asserted-by":"publisher","first-page":"455","DOI":"10.2147\/CCID.S301451","volume":"14","author":"A Alsantali","year":"2021","unstructured":"Alsantali A, Almalki B, Alharbi A. Recalcitrant dissecting cellulitis of the scalp treated successfully with adalimumab with hair regrowth: a case report. Clin Cosmet Investig Dermatol. 2021;14:455\u20138.","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"3720_CR33","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.jdcr.2023.10.011","volume":"42","author":"KN Nagshabandi","year":"2023","unstructured":"Nagshabandi KN, Alsalhi A, Alahmadi D, Almesfer S, Alajlan AM. Refractory dissecting cellulitis of the scalp treated with risankizumab: 2 case reports. JAAD Case Rep. 2023;42:87\u201390.","journal-title":"JAAD Case Rep"},{"issue":"1","key":"3720_CR34","first-page":"e52377","volume":"16","author":"Z Islam","year":"2024","unstructured":"Islam Z, Toker M, Gandhi IM, Sher A, Campton K. Improvement of recalcitrant dissecting cellulitis of the scalp after a trial of upadacitinib. Cureus. 2024;16(1):e52377.","journal-title":"Cureus"},{"key":"3720_CR35","doi-asserted-by":"crossref","unstructured":"Bernard JW, Reddy S, Flowers RH. The successful use of oral apremilast for a case of dissecting cellulitis. JAAD Case Rep. 2023;39:122\u20134.\ufeff","DOI":"10.1016\/j.jdcr.2023.06.033"},{"key":"3720_CR36","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"key":"3720_CR37","unstructured":"National Heart L, and Blood Institute: Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies. 2014."},{"issue":"2","key":"3720_CR38","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1136\/bmjebm-2017-110853","volume":"23","author":"MH Murad","year":"2018","unstructured":"Murad MH, Sultan S, Haffar S, Bazerbachi F. Methodological quality and synthesis of case series and case reports. BMJ Evid Based Med. 2018;23(2):60\u20133.","journal-title":"BMJ Evid Based Med"},{"issue":"2","key":"3720_CR39","first-page":"e0293433","volume":"12","author":"JM Cautela","year":"2020","unstructured":"Cautela JM, Deboli T, Licciardello M, Dapavo P, Broganelli P, Fierro MT. Dissecting cellulitis of the scalp in patients with hidradenitis suppurativa respondinig to adalimumab therapy. J Dermatol Nurses\u2019 Assoc. 2020;12(2):e0293433.","journal-title":"J Dermatol Nurses\u2019 Assoc"},{"key":"3720_CR40","doi-asserted-by":"publisher","first-page":"S292","DOI":"10.1093\/ecco-jcc\/jjy222.499","volume":"13","author":"FM Phillips","year":"2019","unstructured":"Phillips FM, Verstockt B, Sebastian S, Ribaldone DG, Vavricka S, Konstantinos K, Slattery E, De Suray N, Flores C, Fries W, et al. Inflammatory cutaneous lesions in inflammatory bowel disease treated with vedolizumab or ustekinumab: an ECCO CONFER multi-centre case series. J Crohns Colitis. 2019;13:S292\u20133.","journal-title":"J Crohns Colitis"},{"issue":"2","key":"3720_CR41","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1111\/bjd.13999","volume":"174","author":"A Badaoui","year":"2016","unstructured":"Badaoui A, Reygagne P, Cavelier-Balloy B, Pinquier L, Deschamps L, Crickx B, Descamps V. Dissecting cellulitis of the scalp: a retrospective study of 51 patients and review of literature. Br J Dermatol. 2016;174(2):421\u20133.","journal-title":"Br J Dermatol"},{"key":"3720_CR42","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15626","author":"M Gamissans","year":"2022","unstructured":"Gamissans M, Roman\u00ed J, L\u00f3pez-Llunell C, Riera-Mart\u00ed N, Sin M. Dissecting cellulitis of the scalp: a review on clinical characteristics and management options in a series of 14 patients. Dermatol Ther. 2022. https:\/\/doi.org\/10.1111\/dth.15626.","journal-title":"Dermatol Ther"},{"issue":"5","key":"3720_CR43","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1093\/ced\/llad036","volume":"48","author":"M Alzahrani","year":"2023","unstructured":"Alzahrani M, Coste V, Konstantinou MP, Reguiai Z, Villani A, Hotz C, Viguier M, Pruvost-Balland C, Dupuy A, Wolkenstein P, et al. Treatment of dissecting cellulitis of the scalp with tumour necrosis factor inhibitors: a retrospective multicentre study. Clin Exp Dermatol. 2023;48(5):528\u201330.","journal-title":"Clin Exp Dermatol"},{"issue":"3","key":"3720_CR44","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1111\/dth.12222","volume":"28","author":"FL Sand","year":"2015","unstructured":"Sand FL, Thomsen SF. Off-label use of TNF-alpha inhibitors in a dermatological university department: retrospective evaluation of 118 patients. Dermatol Ther. 2015;28(3):158\u201365.","journal-title":"Dermatol Ther"},{"issue":"1","key":"3720_CR45","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1684\/ejd.2021.3969","volume":"31","author":"L Frechet","year":"2021","unstructured":"Frechet L, Puzenat E, Charollais R, Dresco F, Carlet C, Gallais-Serezal I, Nardin C, Aubin F. Dissecting cellulitis of the scalp treated by tumour necrosis factor inhibitors: a case series. Eur J Dermatol. 2021;31(1):81\u20135.","journal-title":"Eur J Dermatol"},{"issue":"5","key":"3720_CR46","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1001\/archdermatol.2010.16","volume":"146","author":"AA Navarini","year":"2010","unstructured":"Navarini AA, Tr\u00fceb RM. 3 cases of dissecting cellulitis of the scalp treated with adalimumab: control of inflammation within residual structural disease. Arch Dermatol. 2010;146(5):517\u201320.","journal-title":"Arch Dermatol"},{"key":"3720_CR47","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-013-0346-y","author":"DT Lim","year":"2013","unstructured":"Lim DT, James NM, Hassan S, Khan MA. Spondyloarthritis associated with acne conglobata, hidradenitis suppurativa and dissecting cellulitis of the scalp: a review with illustrative cases. Curr Rheumatol Rep. 2013. https:\/\/doi.org\/10.1007\/s11926-013-0346-y.","journal-title":"Curr Rheumatol Rep"},{"key":"3720_CR48","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14829","author":"M Sanchez-Diaz","year":"2021","unstructured":"Sanchez-Diaz M, Martinez-Lopez A, Salvador-Rodriguez L, Montero-Vilchez T, Arias-Santiago S, Molina-Leyva A. The role of biologic treatment in special scenarios in hidradenitis suppurativa: facial and nape phenotype, dissecting cellulitis of the scalp, and lymphedema. Dermatol Therapy. 2021. https:\/\/doi.org\/10.1111\/dth.14829.","journal-title":"Dermatol Therapy"},{"key":"3720_CR49","first-page":"98","volume":"171","author":"P Pratsou","year":"2014","unstructured":"Pratsou P, Muc R, Kaur MR. Septal eosinophilic panniculitis associated with adalimumab therapy for dissecting cellulitis of the scalp. Br J Dermatol. 2014;171:98.","journal-title":"Br J Dermatol"},{"issue":"6","key":"3720_CR50","doi-asserted-by":"publisher","first-page":"e199","DOI":"10.1308\/rcsann.2020.7096","volume":"103","author":"J Spiers","year":"2021","unstructured":"Spiers J, Vinnicombe Z, Singh G, Pouncey A, McEvoy H. Severe dissecting scalp cellulitis successfully treated with serial excisions in combination with anti-TNF therapy. Ann R Coll Surg Engl. 2021;103(6):e199\u2013201.","journal-title":"Ann R Coll Surg Engl"},{"key":"3720_CR51","doi-asserted-by":"publisher","first-page":"1132574","DOI":"10.3389\/fmed.2023.1132574","volume":"10","author":"Y Yu","year":"2023","unstructured":"Yu Y, Ding X, Guo F, Ze K, Sun X, Li X. Perifolliculitis capitis abscedens et suffodiens treatment with tumor necrosis factor inhibitors and baricitinib: a case report and literature review. Front Med (Lausanne). 2023;10:1132574.","journal-title":"Front Med (Lausanne)"},{"issue":"8","key":"3720_CR52","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1111\/ced.14789","volume":"46","author":"S Minakawa","year":"2021","unstructured":"Minakawa S, Matsuzaki Y, Rokunohe D, Kumagai N, Kurose A, Kushibiki M, Kayaba H, Sawamura D. Hidradenitis suppurativa with perifolliculitis capitis abscedens et suffodiens successfully treated with a human anti-tumour necrosis factor monoclonal antibody. Clin Exp Dermatol. 2021;46(8):1586\u20138.","journal-title":"Clin Exp Dermatol"},{"issue":"7\u20138","key":"3720_CR53","doi-asserted-by":"publisher","first-page":"e1309","DOI":"10.1093\/milmed\/usz394","volume":"185","author":"E Maxon","year":"2020","unstructured":"Maxon E, Modlin K, Durso TA, Miletta NR. A case report of tumor necrosis factor alpha inhibitors in an active duty service member with dissecting cellulitis of the scalp resistant to treatment. Mil Med. 2020;185(7\u20138):e1309\u201311.","journal-title":"Mil Med"},{"issue":"3","key":"3720_CR54","first-page":"255","volume":"26","author":"I Sjerobabski Masnec","year":"2018","unstructured":"Sjerobabski Masnec I, Franceschi N. Perifolliculitis capitis abscedens et suffodiens treated with anti-tumor necrosis factor-alpha\u2014possible new treatment option. Acta Dermatovenerol Croat. 2018;26(3):255\u201389.","journal-title":"Acta Dermatovenerol Croat"},{"issue":"4","key":"3720_CR55","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1111\/bjd.14269","volume":"174","author":"Y Mansouri","year":"2016","unstructured":"Mansouri Y, Martin-Clavijo A, Newsome P, Kaur MR. Dissecting cellulitis of the scalp treated with tumour necrosis factor-\u03b1 inhibitors: experience with two agents. Br J Dermatol. 2016;174(4):916\u20138.","journal-title":"Br J Dermatol"},{"issue":"2","key":"3720_CR56","first-page":"102","volume":"34","author":"RF Martin-Garc\u00eda","year":"2015","unstructured":"Martin-Garc\u00eda RF, Rull\u00e1n JM. Refractory dissecting cellulitis of the scalp successfully controlled with adalimumab. P R Health Sci J. 2015;34(2):102\u20134.","journal-title":"P R Health Sci J"},{"issue":"3","key":"3720_CR57","first-page":"AB52","volume":"60","author":"S Sukhatme","year":"2009","unstructured":"Sukhatme S, Gottlieb A, Lenzy Y. Dissecting cellulitis of the scalp treated with adalimumab. J Am Acad Dermatol. 2009;60(3):AB52.","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"3720_CR58","doi-asserted-by":"publisher","first-page":"e374","DOI":"10.1111\/1346-8138.15945","volume":"48","author":"I Kurokawa","year":"2021","unstructured":"Kurokawa I. Perifolliculitis capitis abscedens et suffodiens with hidradenitis suppurativa and nodulocystic acne treated with adalimumab. J Dermatol. 2021;48(8):e374\u20135.","journal-title":"J Dermatol"},{"issue":"4","key":"3720_CR59","first-page":"36","volume":"5","author":"U Wollina","year":"2012","unstructured":"Wollina U, Gemmeke A, Koch A. Dissecting cellulitis of the scalp responding to intravenous tumor necrosis factor-alpha antagonist. J Clin Aesthet Dermatol. 2012;5(4):36\u20139.","journal-title":"J Clin Aesthet Dermatol"},{"issue":"2","key":"3720_CR60","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1111\/j.1365-2133.2008.08674.x","volume":"159","author":"HRC Brandt","year":"2008","unstructured":"Brandt HRC, Malheiros APR, Teixeira MG, Machado MCR. Perifolliculitis capitis abscedens et suffodiens successfully controlled with infliximab. Br J Dermatol. 2008;159(2):506\u20137.","journal-title":"Br J Dermatol"},{"issue":"3","key":"3720_CR61","doi-asserted-by":"publisher","first-page":"e8","DOI":"10.14309\/crj.2018.8","volume":"5","author":"TA Syed","year":"2018","unstructured":"Syed TA, Asad ZUA, Salem G, Garg K, Rubin E, Agudelo N. Dissecting cellulitis of the scalp: a rare dermatological manifestation of Crohn\u2019s disease. ACG Case Rep J. 2018;5(3):e8.","journal-title":"ACG Case Rep J"},{"key":"3720_CR62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jdcr.2023.06.041","volume":"39","author":"N Almuhanna","year":"2023","unstructured":"Almuhanna N, Alhamazani R, Alkhezzi S, Alfataih MT, Dakhil AB, Alhamazani YS, Alhomida FA. Successful treatment of dissecting cellulitis with certolizumab pegol in a pregnant patient. JAAD Case Rep. 2023;39:1\u20132.","journal-title":"JAAD Case Rep"},{"issue":"3","key":"3720_CR63","first-page":"313","volume":"21","author":"F Babalola","year":"2022","unstructured":"Babalola F, Chima M, Jobarteh R, Gottlieb A. Refractory dissecting cellulitis of the scalp treated with risankizumab. J Drugs Dermatol. 2022;21(3):313\u20134.","journal-title":"J Drugs Dermatol"},{"issue":"3","key":"3720_CR64","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1111\/ajd.13860","volume":"63","author":"A Awad","year":"2022","unstructured":"Awad A, Sinclair R. Treatment of dissecting cellulitis of the scalp with Tildrakizumab. Australas J Dermatol. 2022;63(3):404\u20136.","journal-title":"Australas J Dermatol"},{"issue":"7","key":"3720_CR65","first-page":"776","volume":"20","author":"V De Bedout","year":"2021","unstructured":"De Bedout V, Harper H, Miteva M, Lev-Tov H. Treatment dissecting cellulitis of the scalp with secukinumab. J Drugs Dermatol. 2021;20(7):776\u20137.","journal-title":"J Drugs Dermatol"},{"issue":"1","key":"3720_CR66","doi-asserted-by":"publisher","first-page":"52","DOI":"10.4103\/jdds.jdds_50_19","volume":"24","author":"S Muzumdar","year":"2020","unstructured":"Muzumdar S, Parikh S, Strober B. Treatment of refractory dissecting cellulitis of the scalp with guselkumab: case report. J Dermatol Dermatol Surg. 2020;24(1):52\u20133.","journal-title":"J Dermatol Dermatol Surg"},{"issue":"10","key":"3720_CR67","first-page":"1068","volume":"29","author":"SG Bellew","year":"2003","unstructured":"Bellew SG, Nemerofsky R, Schwartz RA, Granick MS. Successful treatment of recalcitrant dissecting cellulitis of the scalp with complete scalp excision and split-thickness skin graft. Dermatol Surg. 2003;29(10):1068\u201370.","journal-title":"Dermatol Surg"},{"key":"3720_CR68","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1111\/jocd.16081","volume":"23","author":"S Sadeghi","year":"2023","unstructured":"Sadeghi S, Ghane Y, Hajizadeh N, Goodarzi A. Autologous adipose tissue injection in the treatment of alopecia: a mini-review. J Cosmet Dermatol. 2023;23:758.","journal-title":"J Cosmet Dermatol"},{"issue":"3","key":"3720_CR69","doi-asserted-by":"publisher","first-page":"318","DOI":"10.4103\/0019-5154.82492","volume":"56","author":"G Tchernev","year":"2011","unstructured":"Tchernev G. Folliculitis et perifolliculitis capitis abscedens et suffodiens controlled with a combination therapy: systemic antibiosis (metronidazole plus clindamycin), dermatosurgical approach, and high-dose isotretinoin. Indian J Dermatol. 2011;56(3):318\u201320.","journal-title":"Indian J Dermatol"},{"key":"3720_CR70","doi-asserted-by":"publisher","first-page":"68","DOI":"10.3389\/fmed.2020.00068","volume":"7","author":"SM Seyed Jafari","year":"2020","unstructured":"Seyed Jafari SM, Hunger RE, Schlapbach C. Hidradenitis suppurativa: current understanding of pathogenic mechanisms and suggestion for treatment algorithm. Front Med (Lausanne). 2020;7:68.","journal-title":"Front Med (Lausanne)"},{"issue":"9","key":"3720_CR71","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1007\/s00296-022-05136-x","volume":"42","author":"G Evangelatos","year":"2022","unstructured":"Evangelatos G, Bamias G, Kitas GD, Kollias G, Sfikakis PP. The second decade of anti-TNF-a therapy in clinical practice: new lessons and future directions in the COVID-19 era. Rheumatol Int. 2022;42(9):1493\u2013511.","journal-title":"Rheumatol Int"},{"issue":"5","key":"3720_CR72","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.jaad.2019.08.089","volume":"82","author":"SR Goldburg","year":"2020","unstructured":"Goldburg SR, Strober BE, Payette MJ. Hidradenitis suppurativa: current and emerging treatments. J Am Acad Dermatol. 2020;82(5):1061\u201382.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"3720_CR73","doi-asserted-by":"publisher","first-page":"137","DOI":"10.4161\/mabs.2.2.11271","volume":"2","author":"N Goel","year":"2010","unstructured":"Goel N, Stephens S. Certolizumab pegol. MAbs. 2010;2(2):137\u201347.","journal-title":"MAbs"},{"issue":"2","key":"3720_CR74","first-page":"9566","volume":"15","author":"A Shadid","year":"2023","unstructured":"Shadid A, Alobaida S, Binamer Y. Certolizumab to treat hidradenitis suppurativa. Dermatol Rep. 2023;15(2):9566.","journal-title":"Dermatol Rep"},{"issue":"22","key":"3720_CR75","doi-asserted-by":"publisher","first-page":"8436","DOI":"10.3390\/ijms21228436","volume":"21","author":"E Del Duca","year":"2020","unstructured":"Del Duca E, Morelli P, Bennardo L, Di Raimondo C, Nistic\u00f2 SP. Cytokine pathways and investigational target therapies in hidradenitis suppurativa. Int J Mol Sci. 2020;21(22):8436.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"3720_CR76","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1177\/12034754211035667","volume":"26","author":"N Kashetsky","year":"2022","unstructured":"Kashetsky N, Mufti A, Alabdulrazzaq S, Lytvyn Y, Sachdeva M, Rahat A, Yeung J. Treatment outcomes of IL-17 inhibitors in hidradenitis suppurativa: a systematic review. J Cutan Med Surg. 2022;26(1):79\u201386.","journal-title":"J Cutan Med Surg"},{"key":"3720_CR77","doi-asserted-by":"publisher","first-page":"2525","DOI":"10.2147\/CCID.S418748","volume":"16","author":"F Martora","year":"2023","unstructured":"Martora F, Scalvenzi M, Battista T, Fornaro L, Potestio L, Ruggiero A, Megna M. Guselkumab, risankizumab, and tildrakizumab in the management of hidradenitis suppurativa: a review of existing trials and real-life data. Clin Cosmet Investig Dermatol. 2023;16:2525\u201336.","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"2","key":"3720_CR78","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1080\/09546634.2020.1776208","volume":"33","author":"S Valenzuela-Ubi\u00f1a","year":"2022","unstructured":"Valenzuela-Ubi\u00f1a S, Jim\u00e9nez-Gallo D, Villegas-Romero I, Rodr\u00edguez-Mateos ME, Linares-Barrios M. Effectiveness of ustekinumab for moderate-to-severe hidradenitis suppurativa: a case series. J Dermatol Treat. 2022;33(2):1159\u201362.","journal-title":"J Dermatol Treat"},{"issue":"3","key":"3720_CR79","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41584-021-00726-8","volume":"18","author":"Y Tanaka","year":"2022","unstructured":"Tanaka Y, Luo Y, O\u2019Shea JJ, Nakayamada S. Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach. Nat Rev Rheumatol. 2022;18(3):133\u201345.","journal-title":"Nat Rev Rheumatol"},{"issue":"7","key":"3720_CR80","doi-asserted-by":"publisher","first-page":"4234","DOI":"10.4049\/jimmunol.1003668","volume":"186","author":"K Ghoreschi","year":"2011","unstructured":"Ghoreschi K, Jesson MI, Li X, Lee JL, Ghosh S, Alsup JW, Warner JD, Tanaka M, Steward-Tharp SM, Gadina M, et al. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol. 2011;186(7):4234\u201343.","journal-title":"J Immunol"},{"issue":"6","key":"3720_CR81","doi-asserted-by":"publisher","first-page":"e13646","DOI":"10.1111\/acel.13646","volume":"21","author":"R Kandhaya-Pillai","year":"2022","unstructured":"Kandhaya-Pillai R, Yang X, Tchkonia T, Martin GM, Kirkland JL, Oshima J. TNF-\u03b1\/IFN-\u03b3 synergy amplifies senescence-associated inflammation and SARS-CoV-2 receptor expression via hyper-activated JAK\/STAT1. Aging Cell. 2022;21(6):e13646.","journal-title":"Aging Cell"},{"issue":"9","key":"3720_CR82","doi-asserted-by":"publisher","first-page":"e1500973","DOI":"10.1126\/sciadv.1500973","volume":"1","author":"S Harel","year":"2015","unstructured":"Harel S, Higgins CA, Cerise JE, Dai Z, Chen JC, Clynes R, Christiano AM. Pharmacologic inhibition of JAK-STAT signaling promotes hair growth. Sci Adv. 2015;1(9):e1500973.","journal-title":"Sci Adv"},{"issue":"3","key":"3720_CR83","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s40257-023-00764-w","volume":"24","author":"O Kwon","year":"2023","unstructured":"Kwon O, Senna MM, Sinclair R, Ito T, Dutronc Y, Lin CY, Yu G, Chiasserini C, McCollam J, Wu WS, et al. Efficacy and safety of baricitinib in patients with severe alopecia areata over 52 weeks of continuous therapy in two phase III trials (BRAVE-AA1 and BRAVE-AA2). Am J Clin Dermatol. 2023;24(3):443\u201351.","journal-title":"Am J Clin Dermatol"},{"issue":"6","key":"3720_CR84","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1016\/j.jaad.2022.07.047","volume":"87","author":"E Kozera","year":"2022","unstructured":"Kozera E, Flora A, Frew JW. Real-world safety and clinical response of janus kinase inhibitor upadacitinib in the treatment of hidradenitis suppurativa: a retrospective cohort study. J Am Acad Dermatol. 2022;87(6):1440\u20132.","journal-title":"J Am Acad Dermatol"},{"key":"3720_CR85","doi-asserted-by":"publisher","first-page":"111435","DOI":"10.1016\/j.intimp.2023.111435","volume":"127","author":"A Heidari","year":"2024","unstructured":"Heidari A, Ghane Y, Heidari N, Sadeghi S, Goodarzi A. A systematic review of Janus kinase inhibitors and spleen tyrosine kinase inhibitors for hidradenitis suppurativa treatment. Int Immunopharmacol. 2024;127:111435.","journal-title":"Int Immunopharmacol"},{"issue":"2","key":"3720_CR86","doi-asserted-by":"publisher","first-page":"e0293433","DOI":"10.1371\/journal.pone.0293433","volume":"19","author":"N Hajizadeh","year":"2024","unstructured":"Hajizadeh N, Heidari A, Sadeghi S, Goodarzi A. Tumor necrosis factor inhibitors and janus kinase inhibitors in the treatment of cicatricial alopecia: a systematic review. PLoS ONE. 2024;19(2):e0293433.","journal-title":"PLoS ONE"},{"issue":"12","key":"3720_CR87","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1016\/j.bcp.2012.01.001","volume":"83","author":"P Schafer","year":"2012","unstructured":"Schafer P. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Biochem Pharmacol. 2012;83(12):1583\u201390.","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"3720_CR88","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jaad.2015.03.049","volume":"73","author":"K Papp","year":"2015","unstructured":"Papp K, Reich K, Leonardi CL, Kircik L, Chimenti S, Langley RG, Hu C, Stevens RM, Day RM, Gordon KB, et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and safety trial evaluating the effects of apremilast in psoriasis [ESTEEM] 1). J Am Acad Dermatol. 2015;73(1):37\u201349.","journal-title":"J Am Acad Dermatol"},{"key":"3720_CR89","doi-asserted-by":"publisher","first-page":"1169327","DOI":"10.3389\/fphar.2023.1169327","volume":"14","author":"M Li","year":"2023","unstructured":"Li M, You R, Su Y, Zhou H, Gong S. Characteristic analysis of adverse reactions of five anti-TNF\u0251 agents: a descriptive analysis from WHO-VigiAccess. Front Pharmacol. 2023;14:1169327.","journal-title":"Front Pharmacol"},{"key":"3720_CR90","doi-asserted-by":"publisher","first-page":"993057","DOI":"10.3389\/fimmu.2023.993057","volume":"14","author":"J Wang","year":"2023","unstructured":"Wang J, Wang C, Liu L, Hong S, Ru Y, Sun X, Chen J, Zhang M, Lin N, Li B, et al. Adverse events associated with anti-IL-17 agents for psoriasis and psoriatic arthritis: a systematic scoping review. Front Immunol. 2023;14:993057.","journal-title":"Front Immunol"},{"issue":"4","key":"3720_CR91","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1093\/bjd\/ljad229","volume":"189","author":"C Ertus","year":"2023","unstructured":"Ertus C, Scailteux LM, Lescoat A, Berthe P, Auffret V, Dupuy A, Oger E, Droitcourt C. Major adverse cardiovascular events in patients with atopic dermatitis treated with oral Janus kinase inhibitors: a systematic review and meta-analysis. Br J Dermatol. 2023;189(4):368\u201380.","journal-title":"Br J Dermatol"},{"key":"3720_CR92","doi-asserted-by":"publisher","first-page":"746396","DOI":"10.3389\/fphar.2021.746396","volume":"12","author":"J Li","year":"2021","unstructured":"Li J, Zhang Z, Wu X, Zhou J, Meng D, Zhu P. Risk of adverse events after Anti-TNF treatment for inflammatory rheumatological disease. A Meta-Anal Front Pharmacol. 2021;12:746396.","journal-title":"A Meta-Anal Front Pharmacol"},{"issue":"4","key":"3720_CR93","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1007\/s40744-021-00360-6","volume":"8","author":"SL Truong","year":"2021","unstructured":"Truong SL, Chin J, Liew DFL, Zahir SF, Ryan EG, Rubel D, Radford-Smith G, Robinson PC. Systematic review and meta-analysis of inflammatory bowel disease adverse events with anti-interleukin 17A agents and tumor necrosis factor inhibitors in rheumatic disease and skin psoriasis. Rheumatol Ther. 2021;8(4):1603\u201316.","journal-title":"Rheumatol Ther"},{"issue":"6","key":"3720_CR94","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1111\/jdv.16073","volume":"34","author":"ND Loft","year":"2020","unstructured":"Loft ND, Vaengebjerg S, Halling AS, Skov L, Egeberg A. Adverse events with IL-17 and IL-23 inhibitors for psoriasis and psoriatic arthritis: a systematic review and meta-analysis of phase III studies. J Eur Acad Dermatol Venereol. 2020;34(6):1151\u201360.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"3720_CR95","doi-asserted-by":"publisher","first-page":"1084614","DOI":"10.3389\/fphar.2023.1084614","volume":"14","author":"H Feng","year":"2023","unstructured":"Feng H, Zhao Y, Kuang W, Dai Y, Cen X, Qin F. Adverse events of tumor necrosis factor alpha inhibitors for the treatment of ankylosing spondylitis: a meta-analysis of randomized, placebo-controlled trials. Front Pharmacol. 2023;14:1084614.","journal-title":"Front Pharmacol"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03720-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-03720-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03720-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,18]],"date-time":"2025-05-18T10:02:54Z","timestamp":1747562574000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-025-03720-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,18]]},"references-count":95,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3720"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-03720-5","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,18]]},"assertion":[{"value":"31 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declared no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"236"}}